Clinical Guest Contributors

1. The Cost And ROI Of Agentic AI In Clinical Trials: What Sponsors And CROs Need To Know 7/21/2026

   Beroe Inc. analyst T.G. Prasanna discusses agentic AI for clinical research and how it must be evaluated as a regulated operating cost transformation, with platform, orchestration, compliance, validation, and oversight costs modeled together.

2. Reduce Friction And Save Time: Revamp Site Training To Focus On Value Over Volume 7/21/2026

   TransCelerate BioPharma members Ashlin Dunne, Anne Marie Inglis, and Ann Katrine Miranda assess the state of site training, examine how training affects trial execution, and discuss a better path forward.

3. Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors 7/20/2026

   CuraCell Head of Clinical Operations Torbjörn Ström discusses, in the context of CC-38 and CytoPLY-derived tumor-infiltrating lymphocytes (TILs), the utility of named-patient experience, dosing and preconditioning, and T-cell therapy capabilities in cold solid tumors.

4. What Pistoia Alliance's AI Poll Reveals About Industry Readiness And Regulatory Confidence 7/17/2026

   Pistoia Alliance President Becky Upton, Ph.D., reviews findings from a poll about AI use in clinical research conducted at Clinical Trials Technology Congress (CTTC) that revealed barriers to adoption, early ROI, emerging use cases, and the role of patient-generated data.

5. Early Patient Education And Community Outreach Are Advancing Representation In Clinical Trials 7/16/2026

   Merck Executive Director, Clinical Trial Patient Representation, Adrelia Allen argues that patient awareness, access, early information, and trust shape are the pillars of patient representation in clinical trials.

6. The Promise Of Bispecifics In The Quest For Outpatient Immunotherapy 7/15/2026

   START San Antonio's Drew Rasco, MD, reflects on the evolution of immunotherapy and highlights how novel therapies such as bispecifics are both challenging and intriguing for principal investigators (PIs).

7. Digital Twins Enhance Disease Progression Measurements In FSHD 7/14/2026

   Digital twins can transform trial design by making data more robust and alleviating patient burden. In this interview, Epicrispr CEO Amber Salzman, Ph.D., shares how the company's using it to reliably predict muscle volume change in their trial for a FSHD gene therapy. 

8. 5 Informed Consent Fixes For Sponsors And Investigators 7/14/2026

   Informed consent has never been solely about documentation, but some sponsors has treated it as a checkbox exercise. Here, consultant Tasha Mohseni shares tips and fixs for how best to approach informed consent.

9. Navigating The New EU Pharmaceutical Legislation: Key Implications For Pediatric Drug Development 7/13/2026

   UCB’s Senior Development Strategy Lead Pediatrics Martine Dehlinger-Kremer, Ph.D., discusses updates to the new EU Pharma legislation and how they impact pediatric drug development, including earlier pediatric investigational plans .

10. Why Life Science Tech Pilots Fail After The Demo — And How To Avoid It 7/13/2026

    A working demo might look promising, but it doesn't tell you whether the tech can be shipped, integrated, validated, and accepted by regulator. Tech consultant Lukasz Lazewski explains how to look past the allure and evaluate its true functionality.